According to filings with the U.S. Securities and Exchange Commission, Amplifyer Bio is raising up to $7,078,494.00 in new funding. Sources indicate that as part of senior management President, Eric Huang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amplifyer Bio
Amplifyer Bio, Inc. is an exciting new startup developing technology of transformative potential for the liquid biopsy field and the product of a collaboration between the labs of Dr. Sangeeta Bhatia, Dr. Chris Love and Dr. Viktor Adalsteinsson at MIT and the Broad Institute. The work has been published in Science and has been presented at leading conferences both in the US and internationally. The company is focused on the development of novel priming agents that in combination with current liquid biopsy diagnostics will improve test performance. Amplifyers first program will be focused on increasing cfDNA in blood for cancer diagnostics. This will provide both physicians and patients higher quantity and quality of genomic information related to their cancer, with the aim of improving clinical outcomes.

To learn more about Amplifyer Bio, visit http://amplifyer.bio/
Amplifyer Bio Linkedin Page: https://www.linkedin.com/company/amplifyer-bio/

Contact:
Eric Huang, President
617-417-9885
https://www.linkedin.com/in/eric-huang-0847162/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.